Effectiveness and Safety of Sofosbuvir-Velpatasvir in Patients with Cirrhosis Associated with Genotype 3 Hepatitis C Infection in Xinjiang, China

References

• World Health Organization. Global health sector strategy on viral hepatitis 2016–2021. Geneva, Switzerland: World Health Organization; 2016. Available from: https://apps.who.int/iris/bitstream/handle/10665/246177/WHO-HIV-2016.06-chi.pdf. Accessed May 5, 2022.
   Google Scholar
• Cui Y, Jia J. Update on epidemiology of hepatitis B and C in China. J Gastroenterol Hepatol. 2013;28(Suppl 1):7–10. doi:10.1111/jgh.12220
   PubMed Web of Science ®Google Scholar
• Chen Y, Yu C, Yin X, et al. Hepatitis C virus genotypes and subtypes circulating in Mainland China. Emerg Microbes Infect. 2017;6(11):e95. doi:10.1038/emi.2017.77
   PubMed Web of Science ®Google Scholar
• Yilihamu A, Weng Q, Zhang Y. Genotyping characteristics of hepatitis C virus and its relation with the progress of hepatitis C in Xinjiang. Man Xing Bing Xue Za Zhi. 2020;2020(5):670–673.
   Google Scholar
• Gondeau C, Pageaux GP, Larrey D. Hepatitis C virus infection: are there still specific problems with genotype 3? World J Gastroenterol. 2015;21(42):12101–12113. doi:10.3748/wjg.v21.i42.12101
   Web of Science ®Google Scholar
• Probst A, Dang T, Bochud M, et al. Role of hepatitis C virus genotype 3 in liver fibrosis progression--a systematic review and meta-analysis. J Viral Hepat. 2011;18(11):745–759. doi:10.1111/j.1365-2893.2011.01481.x
   PubMed Web of Science ®Google Scholar
• Shahnazarian V, Ramai D, Reddy M, et al. Hepatitis C virus genotype 3: clinical features, current and emerging viral inhibitors, future challenges. Ann Gastroenterol. 2018;31(5):541–551. doi:10.20524/aog.2018.0281
   Web of Science ®Google Scholar
• Chung RT, Ghany MG, Kim AY; AASLD-IDSA HCV Guidance Panel. Hepatitis C guidance 2018 update: AASLD-IDSA recommendations for testing, managing, and treating hepatitis C virus infection. Clin Infect Dis. 2018;67(10):1477–1492. doi:10.1093/cid/ciy585
   PubMed Web of Science ®Google Scholar
• European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2018. J Hepatol. 2018;69(2):461–511. doi:10.1016/j.jhep.2018.03.026
   PubMed Web of Science ®Google Scholar
• Tapper EB, Afdhal NH. Is 3 the new 1: perspectives on virology, natural history and treatment for hepatitis C genotype 3. J Viral Hepat. 2013;20(10):669–677. doi:10.1111/jvh.12168
   PubMed Web of Science ®Google Scholar
• Chinese Society of Hepatology, & Chinese Society of Infectious Diseases, Chinese Medical Association. Guidelines for the prevention and treatment of hepatitis C (2019 version). Zhonghua Gan Zang Bing Za Zhi. 2019;27:962–979. doi:10.3760/cma.j.issn.1007-3418.2019.12.008
   Google Scholar
• European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C: final update of the series. J Hepatol. 2020;73(5):1170–1218. doi:10.1016/j.jhep.2020.08.018
   PubMed Web of Science ®Google Scholar
• Ghany MG, Morgan TR; AASLD-IDSA Hepatitis C Guidance Panel. Hepatitis C guidance 2019 update: American Association for the Study of Liver Diseases-Infectious Diseases Society of America recommendations for testing, managing, and treating hepatitis C virus infection. Hepatology. 2020;71(2):686–721. doi:10.1002/hep.31060
   PubMed Web of Science ®Google Scholar
• Belperio PS, Shahoumian TA, Loomis TP, et al. Real-world effectiveness of daclatasvir plus sofosbuvir and velpatasvir/sofosbuvir in hepatitis C genotype 2 and 3. J Hepatol. 2019;70(1):15–23. doi:10.1016/j.jhep.2018.09.018
   PubMed Web of Science ®Google Scholar
• Mangia A, Cenderello G, Copetti M, et al. SVR12 higher than 97% in GT3 cirrhotic patients with evidence of portal hypertension treated with SOF/VEL without ribavirin: a nation-wide cohort study. Cells. 2019;8(4):313. doi:10.3390/cells8040313
   Web of Science ®Google Scholar
• von Felden J, Vermehren J, Ingiliz P, et al. High efficacy of sofosbuvir/velpatasvir and impact of baseline resistance-associated substitutions in hepatitis C genotype 3 infection. Aliment Pharmacol Ther. 2018;47(9):1288–1295. doi:10.1111/apt.14592
   Web of Science ®Google Scholar
• Wilton J, Wong S, Yu A, et al. Real-world effectiveness of sofosbuvir/velpatasvir for treatment of chronic hepatitis C in British Columbia, Canada: a population-based cohort study. Open Forum Infect Dis. 2020;7(3):ofaa055. doi:10.1093/ofid/ofaa055
   PubMed Web of Science ®Google Scholar
• Wong YJ, Thurairajah PH, Kumar R, et al. Efficacy and safety of sofosbuvir/velpatasvir in a real-world chronic hepatitis C genotype 3 cohort. J Gastroenterol Hepatol. 2021;36(5):1300–1308. doi:10.1111/jgh.15324
   Web of Science ®Google Scholar
• Wang X, Wei L. Direct-acting antiviral regimens for patients with chronic infection of hepatitis C virus genotype 3 in China. J Clin Transl Hepatol. 2021;9(3):419–427. doi:10.14218/JCTH.2020.00097
   Web of Science ®Google Scholar
• Xu XY, Ding HG, Li WG, et al. Chinese guidelines on management of hepatic encephalopathy in cirrhosis. World J Gastroenterol. 2019;25(36):5403–5422. doi:10.3748/wjg.v25.i36.5403
   PubMed Web of Science ®Google Scholar
• Zarębska-Michaluk D, Jaroszewicz J, Parfieniuk-Kowerda A, et al. Effectiveness and safety of pangenotypic regimens in the most difficult to treat population of genotype 3 HCV infected cirrhotics. J Clin Med. 2021;10(15):3280. doi:10.3390/jcm10153280
   PubMed Web of Science ®Google Scholar
• Soria A, Fava M, Bernasconi DP, et al. Comparison of three therapeutic regimens for genotype-3 hepatitis C virus infection in a large real-life multicentre cohort. Liver Int. 2020;40(4):769–777. doi:10.1111/liv.14386
   Web of Science ®Google Scholar
• Esteban R, Pineda JA, Calleja JL, et al. Efficacy of Sofosbuvir and Velpatasvir, with and without ribavirin, in patients with hepatitis C virus genotype 3 infection and cirrhosis. Gastroenterology. 2018;155(4):1120–1127.e4. doi:10.1053/j.gastro.2018.06.042
   PubMed Web of Science ®Google Scholar
• Wei L, Lim SG, Xie Q, et al. Sofosbuvir-velpatasvir for treatment of chronic hepatitis C virus infection in Asia: a single-arm, open-label, Phase 3 trial. Lancet Gastroenterol Hepatol. 2019;4(2):127–134. doi:10.1016/S2468-1253(18)30343-1
   PubMed Web of Science ®Google Scholar
• Curry MP, O’Leary JG, Bzowej N, et al. Sofosbuvir and Velpatasvir for HCV in patients with decompensated cirrhosis. N Engl J Med. 2015;373(27):2618–2628. doi:10.1056/NEJMoa1512614
   PubMed Web of Science ®Google Scholar
• Takehara T, Sakamoto N, Nishiguchi S, et al. Efficacy and safety of sofosbuvir-velpatasvir with or without ribavirin in HCV-infected Japanese patients with decompensated cirrhosis: an open-label phase 3 trial. J Gastroenterol. 2019;54(1):87–95. doi:10.1007/s00535-018-1503-x
   Web of Science ®Google Scholar
• Jacobson IM, Lawitz E, Gane EJ, et al. Efficacy of 8 weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir in patients with chronic HCV infection: 2 phase 3 randomized trials. Gastroenterology. 2017;153(1):113–122. doi:10.1053/j.gastro.2017.03.047
   PubMed Web of Science ®Google Scholar
• Flamm SL, Lawitz E, Borg B, et al. High efficacy and improvement in CPT class with sofosbuvir/velpatasvir plus ribavirin for 12 weeks in patients with CPT C decompensated cirrhosis. Gastroenterology. 2019;156:S–1219. doi:10.1016/S0016-5085(19)40032-2
   Web of Science ®Google Scholar
• Kwong A, Kim WR, Mannalithara A, et al. Decreasing mortality and disease severity in hepatitis C patients awaiting liver transplantation in the United States. Liver Transpl. 2018;24(6):735–743. doi:10.1002/lt.24973
   PubMed Web of Science ®Google Scholar